Tardivon Anne A, Ollivier Liliane, El Khoury Carl, Thibault Fabienne
Department of Radiology, Institut Curie, 26 rue d'Ulm, 75248, Paris, Cedex 05, France.
Eur Radiol. 2006 Nov;16(11):2549-58. doi: 10.1007/s00330-006-0317-z. Epub 2006 May 30.
The aim of imaging during and after neoadjuvant therapy is to document and quantify tumor response: has the tumor size been accurately measured? Certainly, the most exciting information for the oncologists is: can we identify good or nonresponders, and can we predict the pathological response early after the initiation of treatment? This review article will discuss the role and the performance of the different imaging modalities (mammography, ultrasound, magnetic resonance imaging and FDG-PET imaging) for evaluating this therapeutic response. It is important to emphasize that, at this time, clinical examination and conventional imaging (mammography and ultrasound) are the only methods recognized by the international criteria. Magnetic resonance imaging and FDG-PET imaging are very promising for predicting the response early after the initiation of neoadjuvant chemotherapy.
肿瘤大小是否得到准确测量？当然，对肿瘤学家来说最令人兴奋的信息是：我们能否识别出反应良好者或无反应者，以及能否在治疗开始后早期预测病理反应？这篇综述文章将讨论不同成像模态（乳腺钼靶、超声、磁共振成像和氟代脱氧葡萄糖正电子发射断层显像）在评估这种治疗反应中的作用和性能。需要强调的是，目前临床检查和传统成像（乳腺钼靶和超声）是国际标准认可的唯一方法。磁共振成像和氟代脱氧葡萄糖正电子发射断层显像在预测新辅助化疗开始后早期的反应方面非常有前景。
